The FDA has approved the first vaccine for RSV
Every year, RSV is responsible for 60,000–120,000 hospitalizations and 6000–10,000 deaths among US adults older than age, according to the FDA. Older adults with underlying health conditions — such as diabetes, a weakened immune system, or lung or heart disease — are at high risk for severe disease.
The FDA approval of Arexvy was based on a clinical study of approximately 25,000 patients. Half of these patients received Arexvy, while the other half received a placebo. Researchers found that the RSV vaccine reduced RSV-associated lower respiratory tract disease by nearly 83% and reduced the risk of developing severe RSV-associated LRTD by 94%.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
FDA approves world's first RSV vaccine, a shot for adults ages 60 and upBREAKING: FDA approves the world's first respiratory syncytial virus, or RSV, vaccine made by pharmaceutical giant GSK.
Lire la suite »
FDA approves world’s first RSV vaccine, a shot for older adultsIn a late-stage clinical trial, the single-dose shot lowered the risk of symptomatic illness by 83% and of severe illness by 94%.
Lire la suite »
FDA Approves World’s First RSV Vaccine for Adults 60 and OlderResearchers first began attempting to develop a vaccine for respiratory syncytial virus, which is of particular danger to older people and infants, around 60 years ago.
Lire la suite »
FDA approves GSK's RSV vaccine for older adults, world's first shot against virusThe FDA's approval is a victory for GSK in a race against Pfizer and Moderna to bring a shot that targets respiratory syncytial virus to the market.
Lire la suite »
FDA approves first vaccine for RSV, a moment six decades in the making | CNNAfter a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV -- and more are on the way.
Lire la suite »